Ebun Garner Biography and Net Worth

General Counsel of Erasca

Ebun is Erasca’s General Counsel and Corporate Secretary. He has represented publicly traded life science companies for over 20 years and has served as an in-house counsel since 2005. During his career, Ebun has been General Counsel or Assistant General Counsel at early stage biopharmaceutical companies and a medical device company, including Imbria Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals and Alphatec Spine. At each company, he provided legal support with respect to product development, business development, corporate finance and public company reporting. Prior to his in-house positions, he was a corporate associate at the New York office of the law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo.

Ebun earned a B.A. in economics from the University of Pennsylvania and a J.D. from New York University School of Law.

What is Ebun Garner's net worth?: The estimated net worth of Ebun Garner is at least $245.12 thousand as of January 7th, 2026. Garner owns 25,076 shares of Erasca stock worth more than $245,118 as of January 21st. This net worth approximation does not reflect any other assets that Garner may own. Additionally, Garner receives an annual salary of $607,440.00 as General Counsel at Erasca. Learn More about Ebun Garner's net worth.
How old is Ebun Garner?: Garner is currently 52 years old. There are 6 older executives and no younger executives at Erasca. The oldest executive at Erasca is Dr. Michael D. Varney Ph.D., Chairman of Research & Development, Scientific Advisory Board Member and Director, who is 66 years old. Learn More on Ebun Garner's age.
What is Ebun Garner's salary?: As the General Counsel of Erasca, Inc., Garner earns $607,440.00 per year. There are 2 executives that earn more than Garner. The highest earning executive at Erasca is Dr. Jonathan E. Lim M.D., Co-Founder, Chairman & CEO, who commands a salary of $987,700.00 per year. Learn More on Ebun Garner's salary.
How do I contact Ebun Garner?: The corporate mailing address for Garner and other Erasca executives is , , . Erasca can also be reached via phone at 858-465-6511 and via email at [email protected]. Learn More on Ebun Garner's contact information.
Has Ebun Garner been buying or selling shares of Erasca?: Within the last three months, Ebun Garner has sold $670,800.00 of Erasca stock. Most recently, Ebun Garner sold 120,000 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $5.59, for a transaction totalling $670,800.00. Following the completion of the sale, the general counsel now directly owns 25,076 shares of the company's stock, valued at $140,174.84. Learn More on Ebun Garner's trading history.
Who are Erasca's active insiders?: Erasca's insider roster includes Alexander Casdin (Director), Ebun Garner (General Counsel), Valerie Harding (Director), and Jonathan Lim (Chairman, CEO and Co-founder). Learn More on Erasca's active insiders.
Are insiders buying or selling shares of Erasca?: During the last year, insiders at the sold shares 1 times. They sold a total of 120,000 shares worth more than $670,800.00. The most recent insider tranaction occured on January, 7th when General Counsel Ebun Garner sold 120,000 shares worth more than $670,800.00. Insiders at Erasca own 14.4% of the company. Learn More about insider trades at Erasca.
Information on this page was last updated on 1/7/2026.

Ebun Garner Insider Trading History at Erasca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/7/2026	Sell	120,000	$5.59	$670,800.00	25,076

Ebun Garner Buying and Selling Activity at Erasca

Erasca Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Today's Range

Now: $9.78

$8.77

$9.81

50 Day Range

MA: $4.17

$2.54

$9.81

2 Week Range

Now: $9.78

$1.01

$10.42

Volume

4,581,086 shs

Average Volume

11,294,220 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Ebun Garner Biography and Net Worth

What is Ebun Garner's net worth?

How old is Ebun Garner?

What is Ebun Garner's salary?

How do I contact Ebun Garner?

Has Ebun Garner been buying or selling shares of Erasca?

Who are Erasca's active insiders?

Are insiders buying or selling shares of Erasca?